Similar articles for PMID: 17609424

Year	Number of Results
1990	1
1993	1
1995	1
1996	2
1997	3
1998	1
1999	2
2000	3
2001	4
2002	6
2003	5
2004	9
2005	5
2006	5
2007	3
2008	2
2009	5
2011	4
2012	1
2013	3
2014	10
2015	3
2016	4
2017	3
2018	5
2019	3
2020	4
2021	1
2022	2
2024	0

1

Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer.

Bollard CM, Gottschalk S, Leen AM, Weiss H, Straathof KC, Carrum G, Khalil M, Wu MF, Huls MH, Chang CC, Gresik MV, Gee AP, Brenner MK, Rooney CM, Heslop HE. Bollard CM, et al. Blood. 2007 Oct 15;110(8):2838-45. doi: 10.1182/blood-2007-05-091280. Epub 2007 Jul 3. Blood. 2007. PMID: 17609424 Free PMC article. Clinical Trial.

2

Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins.

Bollard CM, Gottschalk S, Torrano V, Diouf O, Ku S, Hazrat Y, Carrum G, Ramos C, Fayad L, Shpall EJ, Pro B, Liu H, Wu MF, Lee D, Sheehan AM, Zu Y, Gee AP, Brenner MK, Heslop HE, Rooney CM. Bollard CM, et al. J Clin Oncol. 2014 Mar 10;32(8):798-808. doi: 10.1200/JCO.2013.51.5304. Epub 2013 Dec 16. J Clin Oncol. 2014. PMID: 24344220 Free PMC article. Clinical Trial.

3

Recognition of Epstein-Barr virus-associated gastric carcinoma cells by cytotoxic T lymphocytes induced in vitro with autologous lymphoblastoid cell line and LMP2-derived, HLA-A24-restricted 9-mer peptide.

Okugawa K, Itoh T, Kawashima I, Takesako K, Mazda O, Nukaya I, Yano Y, Yamamoto Y, Yamagishi H, Ueda Y. Okugawa K, et al. Oncol Rep. 2004 Oct;12(4):725-31. Oncol Rep. 2004. PMID: 15375491

4

Good manufacturing practice-grade cytotoxic T lymphocytes specific for latent membrane proteins (LMP)-1 and LMP2 for patients with Epstein-Barr virus-associated lymphoma.

Bollard CM, Gottschalk S, Helen Huls M, Leen AM, Gee AP, Rooney CM. Bollard CM, et al. Cytotherapy. 2011 May;13(5):518-22. doi: 10.3109/14653249.2011.561983. Epub 2011 Mar 1. Cytotherapy. 2011. PMID: 21361747 Free PMC article. No abstract available.

5

The generation and characterization of LMP2-specific CTLs for use as adoptive transfer from patients with relapsed EBV-positive Hodgkin disease.

Bollard CM, Straathof KC, Huls MH, Leen A, Lacuesta K, Davis A, Gottschalk S, Brenner MK, Heslop HE, Rooney CM. Bollard CM, et al. J Immunother. 2004 Jul-Aug;27(4):317-27. doi: 10.1097/00002371-200407000-00008. J Immunother. 2004. PMID: 15235393

6

Cytotoxic T lymphocyte therapy for Epstein-Barr virus+ Hodgkin's disease.

Bollard CM, Aguilar L, Straathof KC, Gahn B, Huls MH, Rousseau A, Sixbey J, Gresik MV, Carrum G, Hudson M, Dilloo D, Gee A, Brenner MK, Rooney CM, Heslop HE. Bollard CM, et al. J Exp Med. 2004 Dec 20;200(12):1623-33. doi: 10.1084/jem.20040890. J Exp Med. 2004. PMID: 15611290 Free PMC article.

7

Cell therapy of stage IV nasopharyngeal carcinoma with autologous Epstein-Barr virus-targeted cytotoxic T lymphocytes.

Comoli P, Pedrazzoli P, Maccario R, Basso S, Carminati O, Labirio M, Schiavo R, Secondino S, Frasson C, Perotti C, Moroni M, Locatelli F, Siena S. Comoli P, et al. J Clin Oncol. 2005 Dec 10;23(35):8942-9. doi: 10.1200/JCO.2005.02.6195. Epub 2005 Oct 3. J Clin Oncol. 2005. PMID: 16204009 Free article. Clinical Trial.

8

Enhanced antilymphoma efficacy of CD19-redirected influenza MP1-specific CTLs by cotransfer of T cells modified to present influenza MP1.

Cooper LJ, Al-Kadhimi Z, Serrano LM, Pfeiffer T, Olivares S, Castro A, Chang WC, Gonzalez S, Smith D, Forman SJ, Jensen MC. Cooper LJ, et al. Blood. 2005 Feb 15;105(4):1622-31. doi: 10.1182/blood-2004-03-1208. Epub 2004 Oct 26. Blood. 2005. PMID: 15507526 Free article.

9

Epstein-Barr Virus (EBV)-derived BARF1 encodes CD4- and CD8-restricted epitopes as targets for T-cell immunotherapy.

Kalra M, Gerdemann U, Luu JD, Ngo MC, Leen AM, Louis CU, Rooney CM, Gottschalk S. Kalra M, et al. Cytotherapy. 2019 Feb;21(2):212-223. doi: 10.1016/j.jcyt.2018.08.001. Epub 2018 Nov 2. Cytotherapy. 2019. PMID: 30396848 Free PMC article.

10

Adoptive transfer of allogeneic Epstein-Barr virus (EBV)-specific cytotoxic T cells with in vitro antitumor activity boosts LMP2-specific immune response in a patient with EBV-related nasopharyngeal carcinoma.

Comoli P, De Palma R, Siena S, Nocera A, Basso S, Del Galdo F, Schiavo R, Carminati O, Tagliamacco A, Abbate GF, Locatelli F, Maccario R, Pedrazzoli P. Comoli P, et al. Ann Oncol. 2004 Jan;15(1):113-7. doi: 10.1093/annonc/mdh027. Ann Oncol. 2004. PMID: 14679129 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

87 results

Results by year